M&A Deal Summary

Epirus Biopharmaceuticals Acquires Bioceros BV

On September 9, 2015, Epirus Biopharmaceuticals acquired life science company Bioceros BV for 14M USD

Acquisition Highlights
  • This is Epirus Biopharmaceuticals’ 2nd transaction in the Life Science sector.
  • This is Epirus Biopharmaceuticals’ largest (disclosed) transaction.
  • This is Epirus Biopharmaceuticals’ 1st transaction in the Netherlands.

M&A Deal Summary
Date 2015-09-09
Target Bioceros BV
Sector Life Science
Buyer(s) Epirus Biopharmaceuticals
Deal Type Add-on Acquisition
Deal Value 14M USD

Target

Bioceros BV

Utrecht, Netherlands
Bioceros BV is a biopharmaceutical R&D company focused on the development of mAbs and generation of GMP-ready cell lines. Over the past decade, Bioceros has developed numerous biosimilar cell lines from its proprietary, well-characterized CHO platform (CHOBC®)i.

Search 198,123 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Epirus Biopharmaceuticals

Boston, Massachusetts, United States
Category Company
Founded 2011
Sector Life Science
Employees73
DESCRIPTION

Epirus Biopharmaceuticals is a biopharmaceutical company, develops, manufactures and commercializes biosimilar therapeutics worldwide. Epirus Biopharmaceuticals is based in Boston, Massachusetts.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 1 of 1
Country (Netherlands) 1 of 1
Year (2015) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-07-15 Zalicus

Cambridge, Massachusetts, United States

Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and inflammation.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-10-14 Zalicus Pharmaceuticals

Vancouver, British Columbia, Canada

Zalicus Pharmaceuticals Ltd. is a pharmaceutical company developer of biosimilar drugs.

Sell $4M
Mergr

Product

Company

Legal